Program
SIM0532
A development code. Also written as “SIM0532 Tablets”.
Its studies are led by Simcere Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Simcere Pharmaceutical Group | 11 open or running | phase 1since Aug 3, 2026 | Aug 3, 2026 | Jun 30, 2028phase 1 · NCT07749703 |
Also a collaborator on its studies: Shanghai Xianwei Medical Technology.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 3, 2026First study: phase 1 study in Histologically or Cytologically Confirmed Advanced Solid TumorsFirst studyNCT07749703 · 346 enrolled · China
Ahead
- Jun 30, 2028Primary completion: phase 1 study in Histologically or Cytologically Confirmed Advanced Solid TumorsNCT07749703
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07749703Histologically or Cytologically Confirmed Advanced Solid Tumors · China | 1 | Active, not recruiting | Jun 30, 2028 | 346 |
How it is read
Names in the registry
- “SIM0532 Tablets”, 1 entry
Codes read as this program: SIM0532.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.